Search Result

Results for "

hyponatremia

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Autophagy (2) Isotope-Labeled Compounds (1) Mineralocorticoid Receptor (2) Opioid Receptor (1) Reference Standards (2) Sodium Channel (2) Vasopressin Receptor (8)
By Research Areas:	Cancer (9) Cardiovascular Disease (7) Endocrinology (7) Inflammation/Immunology (2) Metabolic Disease (6) Neurological Disease (1)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-17000

Tolvaptan Maximum Cited Publications 16 Publications Verification OPC-41061	Vasopressin Receptor Autophagy	Cardiovascular Disease Endocrinology Cancer
Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V₂R) antagonist with an IC₅₀ of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation. Tolvaptan induces cell apoposis and affects cell cycle. Tolvaptan can be used for the research of hyponatremia .

HY-18346

Mozavaptan 1 Publications Verification OPC-31260	Vasopressin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology Cancer
Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V₂ receptor antagonist with an IC₅₀ of 14 nM. Mozavaptan shows ~85-fold selectivity for V₂ receptor over V₁ receptor (IC₅₀ of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .

HY-123593

Mozavaptan hydrochloride 1 Publications Verification OPC-31260 hydrochloride	Vasopressin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology Cancer
Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V₂ receptor antagonist with an IC₅₀ of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V₂ receptor over V₁ receptor (IC₅₀ of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .

HY-B1203

Fludrocortisone 9α-Fludrocortisone; 9α-Fluorcortisol	Mineralocorticoid Receptor Sodium Channel	Inflammation/Immunology Cancer
Fludrocortisone inhibits natriuresis. Fludrocortisone is a synthetic mineralocorticoid with anti-inflammatory activity. Fludrocortisone can be studied in research for small cell lung cancer with profound hyponatremia and acute neurological symptoms as well as aneurysmal subarachnoid hemorrhage .

HY-18344

Satavaptan SR 121463	Vasopressin Receptor	Metabolic Disease
Satavaptan (SR 121463) is an antagonist for vasopressin V2 receptor. Satavaptan regulates the vasopressin regulated phosphopeptides and vasopressin-mediated signaling pathway. Satavaptan is potential in ameliorating hyponatremia .

HY-106234

ZP 120C	Opioid Receptor	Cardiovascular Disease Neurological Disease
ZP 120C is a potent and partial ORL1 receptor agonist. ZP 120C inhibits electrically induced contraction. ZP 120C can be used in the research of hyponatremia/hypokalemia .

HY-17000R

Tolvaptan (Standard) OPC-41061 (Standard)	Reference Standards Vasopressin Receptor Autophagy	Cardiovascular Disease Endocrinology Cancer
Tolvaptan (Standard) is the analytical standard of Tolvaptan. This product is intended for research and analytical applications. Tolvaptan is a selective, competitive and orally active vasopressin receptor 2 (V2R) antagonist with an IC50 of 1.28 μM for the inhibition of arginine vasopressin (AVP)-induced platelet aggregation. Tolvaptan induces cell apoposis and affects cell cycle. Tolvaptan can be used for the research of hyponatremia .

HY-123593R

Mozavaptan hydrochloride (Standard)	Vasopressin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology Cancer
Mozavaptan (hydrochloride) (Standard) is the analytical standard of Mozavaptan (hydrochloride). This product is intended for research and analytical applications. Mozavaptan hydrochloride (OPC-31260 hydrochloride) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan hydrochloride shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan hydrochloride has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .

HY-18346R

Mozavaptan (Standard)	Vasopressin Receptor	Cardiovascular Disease Metabolic Disease Endocrinology Cancer
Mozavaptan (Standard) is the analytical standard of Mozavaptan. This product is intended for research and analytical applications. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V2 receptor antagonist with an IC50 of 14 nM. Mozavaptan shows ~85-fold selectivity for V2 receptor over V1 receptor (IC50 of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .

HY-B1203R

Fludrocortisone (Standard) 9α-Fludrocortisone (Standard); 9α-Fluorcortisol (Standard)	Reference Standards Mineralocorticoid Receptor Sodium Channel	Inflammation/Immunology Cancer
Fludrocortisone (Standard) is the analytical standard of Fludrocortisone. This product is intended for research and analytical applications. Fludrocortisone inhibits natriuresis. Fludrocortisone is a synthetic mineralocorticoid with anti-inflammatory activity. Fludrocortisone can be studied in research for small cell lung cancer with profound hyponatremia and acute neurological symptoms as well as aneurysmal subarachnoid hemorrhage .

HY-18346S

Mozavaptan-d6 OPC-31260-d₆	Isotope-Labeled Compounds Vasopressin Receptor	Metabolic Disease Endocrinology Cancer
Mozavaptan-d6 (OPC-31260-d6) is the deuterium labeled Mozavaptan. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V₂ receptor antagonist with an IC₅₀ of 14 nM. Mozavaptan shows ~85-fold selectivity for V₂ receptor over V₁ receptor (IC₅₀ of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .

ZP 120C	Opioid Receptor	Cardiovascular Disease Neurological Disease
ZP 120C is a potent and partial ORL1 receptor agonist. ZP 120C inhibits electrically induced contraction. ZP 120C can be used in the research of hyponatremia/hypokalemia .

Cat. No.	Product Name	Chemical Structure

HY-18346S

Mozavaptan-d6
Mozavaptan-d6 (OPC-31260-d6) is the deuterium labeled Mozavaptan. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V₂ receptor antagonist with an IC₅₀ of 14 nM. Mozavaptan shows ~85-fold selectivity for V₂ receptor over V₁ receptor (IC₅₀ of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .

Mozavaptan-d6

Mozavaptan-d6 (OPC-31260-d6) is the deuterium labeled Mozavaptan. Mozavaptan (OPC-31260) is a benzazepine derivative and a potent, selective, competitive and orally active vasopressin V₂ receptor antagonist with an IC₅₀ of 14 nM. Mozavaptan shows ~85-fold selectivity for V₂ receptor over V₁ receptor (IC₅₀ of 1.2 μM), and can antagonize the antidiuretic action of arginine vasopressin (AVP) in vivo. Mozavaptan has the potential for hyponatremia, syndrome of inappropriate antidiuretic hormone (SIADH), and congestive heart failure treatment .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.